.webp)
Meet Remi
Remi: AI built for cancer care, not adapted to it
Remi is Cureety’s conversational assistant for patients between visits. Patients describe how they feel in their own words, by text. Remi structures what they share and brings in our oncology-trained clinicians when a situation needs human attention.
The conversational layer
Just a text message away, 24/7
No app, no portal, no password. Patients reach Remi by text message, at any hour. Your team or our Cureety Care Team receives structured information, not a stream of messages.


Compare Remi
Oncology AI vs. general-purpose chatbots
Specialized AI with human oversight
Remi
Built for oncology
Every conversation runs within clinical protocols, with oncology nurses ready to take over.
Generic AI
General-purpose AI
Built for everything
No clinical protocol, no clinician behind the answer. Subjective questions, uncertain outputs.

AI with human oversight
The same symptom does not always carry the same risk
Grade 1 dyspnea
Patient on Pembrolizumab
Low-risk signal
Grade 1 dyspnea
Patient on Trastuzumab Deruxtecan
ILD Risk
A patient with Grade 1 dyspnea on Pembrolizumab may not have a high risk. The same symptom in a patient receiving Trastuzumab Deruxtecan could indicate a high risk of interstitial lung disease. Cureety's intelligence layer ensures triage is aligned with the regimen's toxicity profile.
Over 1 million questionnaires completed · validated algorithm with 94.4% specificity and 95.8% sensitivity for critical classifications. {tooltip} Positea-va study. The algorithm correctly identifies 95.8% of patients classified as "critical" by experts. Only 5.6% false positives.Peer-reviewed and validated over 400 patients. {a:https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.1605}Source{/a}{/tooltip}